We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
InteRNA and Radboud University to Develop microRNA-based Therapeutics for Prostate Cancer
News

InteRNA and Radboud University to Develop microRNA-based Therapeutics for Prostate Cancer

InteRNA and Radboud University to Develop microRNA-based Therapeutics for Prostate Cancer
News

InteRNA and Radboud University to Develop microRNA-based Therapeutics for Prostate Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "InteRNA and Radboud University to Develop microRNA-based Therapeutics for Prostate Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

InteRNA Technologies B.V. and Radboud University Nijmegen Medical Centre have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for prostate cancer.

Under the research collaboration with Professor Jack Schalken (Laboratory of Experimental Urology), InteRNA's lentiviral-based miRNA overexpression library will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in prostate cancer.

"We are very excited about this collaboration with professor Schalken, a renowned investigator in the prostate cancer field, as it allows for functional screens in diverse cell based assays embedded in a lab with extensive knowledge of prostate cancer," said Roel Schaapveld, Chief Operating Officer of InteRNA Technologies.

"Through the collaboration with InteRNA we gain access to a unique functional tool to identify microRNAs that are implicated in prostate carcinogenesis. Thus it is a truly symbiotic public-private partnership!" said professor Jack Schalken of Radboud UNMC.
Advertisement